ClinicalTrials.gg
RecruitingNCT06927466Updated Aug 17, 2026

A Clinical Study to Evaluate the Safety, Tolerability, and Preliminary Efficacy of B019 Injection in Subjects With Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia.

A Phase 1 interventional study of B019 in Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia, sponsored by Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.. Recruiting at 8 sites in China. Open to participants aged 3 Years to 25 Years. Per ClinicalTrials.gov, last updated 2026-08-17.

Primary conditionnone(registry's first term: Recurrence)No conditionIs this wrong?Recurrence describes something many studies share rather than a condition a study is about. The study names no condition we can place it under, so it is not compared with other studies by condition.

Sponsored by Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd. · Phase 1, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Sep 2024, registered Apr 2025).
  • Started Sep 2024; still recruiting 2 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
33
Allocation
Not applicable
Ages
3 Years to 25 Years
Sex
All
01

Study summary

The purpose of the study is to evaluate the safety and tolerability of B019 in subjects.

02

Conditions studied

  • Relapsed or Refractory B-cell Acute Lymphoblastic Leukemia

Browse trials for

03

In context

Lead sponsor

Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd. is the lead sponsor of 2 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
3 Years to 25 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. The patient himself/herself , and/or his/her legal guardian, agree to participate in the trial and sign the form;
  2. Meet the diagnostic criteria for recurrent or acute B cell lymphoblastic leukemia;
  3. Documentation of CD19/CD22 tumor expression

3. Liver, kidney, lung and heart function meet requirements; 4. Expected survival >3 months; 5. Women of childbearing age and all post-adolescent male participants are willing to use highly effective methods within 1 year after the infusion of B019 injection. At the same time, the subject should promise not to donate eggs or sperm for assisted reproduction for 1 year after the cell infusion.

-

Exclusion criteria

Exclusion Criteria:

  1. Active CNS involvement by ;
  2. Isolated extramedullary leukemia recurrence;
  3. Subjects with ≥grade 2 acute or moderate to severe chronic (GVHD) within 4 weeks prior to screening;
  4. Has had treatment with any prior CAR-T therapy or other therapy abandoned in protocal.

4. Subjects who received therapy abandoned in protocal before PBMC (peripheral blood mononuclear cells) collection or before B019 injection; 5.Active other malignancy in 5 years. 6. Subjects who are positive for any of , HBeAg, HBeAb, HBcAb, , EBV DNA, CMV DNA, HTLV-ab.

7. Other situations deemed inappropriate for participation in this study by the investigator.

-

Terms in these criteria, in plain language(8)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
33 participants (estimated)

Study arms

  • Experimental
    B019

    Biological: B019

Interventions

  • BiologicalB019

    B019: Intravenous infusion, 1.0×10\^6 CAR T cell/kg-10.0×10\^6 CAR T cell/kg

06

What researchers measure

Primary outcomes

  1. (一) Incidence of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Incidence of Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)

    Time frame: Approximately 2 years

Secondary outcomes

  1. The overall response rate (ORR)

    Tumor response will be evaluated according to the Response Evaluation Criteria Solid Tumors (RECIST) criteria version 1.1.

    Time frame: 3 months

  2. Overall Survival (OS)

    Determination of the overall survival times of all patients.

    Time frame: Approximately 2 years

  3. PK(Pharmacokinetics):Tmax

    Time to peak plasma concentration (Tmax)

    Time frame: Approximately 2 years

  4. PK(Pharmacokinetics):Cmax

    Maximum serum concentration(Cmax)

    Time frame: Approximately 2 years

07

Study locations

8 of 8 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Sep 2024 (actual). Primary completion is estimated for Dec 2026, 27 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 7, 2025
First posted
Apr 15, 2025
StartActual
Sep 19, 2024
Primary completionEst.
Dec 31, 2026
CompletionEst.
Jun 30, 2028
Last update
Aug 17, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 17, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT06927466
Lead sponsor
Shanghai Pharmaceutical Group Biological Therapy Technology Co., Ltd.
Responsible party
Sponsor
First posted
Apr 15, 2025
Start date
Sep 19, 2024
Primary completion
Dec 31, 2026 (estimated)
Completion
Jun 30, 2028 (estimated)
Last update
Aug 17, 2026

Study contacts

Jing Chen
Contact
chenjing@scmc.com.cn
0086-021-38626161

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion